The basic process of antigen presentation by MHC class I and II molecules has been resolved over the years by many groups. Many new discoveries first presented at the APP meeting have been published in leading journals in later years and we expect that many new findings will be presented at the upcoming meeting. The knowledge generated in these studies has also translated into clinical applications such as immunotherapy of cancer, immunological monitoring (MHC tetramers) and immunomodulation of autoimmune diseases. We plan in this workshop new sessions in the areas of cancer immunotherapy, vaccination, transplantation immunology and auto-immunity to illustrate the translation of fundamental findings into clinical practice.

This workshop is limited to around 120 participants. These include the leading scientists in this field but will also include young scientists already contributing to research in this field and expected to make future contributions.